Posters
« Back
VALIDATION OF KRISHZYME FACTOR IIa CHROMOGENIC ASSAY FOR TESTING OF TINZAPARIN AND TINZAPARIN INJECTION
EP26519
Poster Title: VALIDATION OF KRISHZYME FACTOR IIa CHROMOGENIC ASSAY FOR TESTING OF TINZAPARIN AND TINZAPARIN INJECTION
Submitted on 05 Oct 2017
Author(s): DR AMITABHA DE
Affiliations: KRISHGEN BIOSYSTEMS
Poster Views: 672
View poster »


Poster Information
Abstract: The inhibitory effect of anti-thrombin III (AT-III) on thrombin,
factor IIa and other coagulation serine proteases in plasma is
increased several thousand-fold by Tinzaparin. This inhibition
accountsfor the anticoagulant effect of Tinzaparin.

The quantitative determination of Tinzaparin levels by the
measurement of their anti-IIa activity is a necessary tool for
monitoring treatment efficacy.

Presence of Tinzaparin catalyzes the reaction between factor IIa and
AT-III. The factor IIa inhibition test is the most useful assay covering
the widest variety of Tinzaparin preparations.

In the assay, the rate of factor IIa inhibition is directly proportional to
the Tinzaparin concentration since both factor IIa and AT-III are in
excess. The residual factor IIa activity is inversely proportional
to the Tinzaparin concentration.

The assay was validated using Tinzaparin Sodium EPRS.

The assay kits manufactured by KRISHGEN BIOSYSTEMS are validated
Chromogenic Assays for the determination of Tinzaparin using anti-lla activity in human plasma successfully met all standard assay-validation parameters and were suitable for use in bioequivalence studies.
Summary: KRISHZYME FIIa Assay kit is a chromogenic assay intended for the
quantitative determination of Tinzaparin / Tinzaparin Sodium in
purified solutions by measurement of factor IIa inhibition activity. The
kit can be used for 100 test reactions as per microtiter plate protocol.
Report abuse »
Questions
Ask the author a question about this poster.
Ask a Question »

Creative Commons

Related Posters


Multiplex miRNA Profiling for Biomarker Discovery and Verification Studies Using the FirePlex® Platform
M. Tackett, B. Heinrich, I. Diwan, G. Tejada, C. Rafferty, E. Atabakhsh, and D. Pregibon

Accelerating high-throughput screening with FirePlex®-HT:An automatable, multiplex immunoassay using FirePlex® Particle Technology
A. Perea, B. Heinrich, W. Austin, C. Rafferty, M. Camilleri, L. To, E. Atabakhsh, and D. Pregibon

riboPOOL: Affordable Custom/Ribosomal RNA Depletion Against Any Species for RNA-Seq
Catherine Goh1, Andrew Walsh1, Michaela Beitzinger1, Jonas Bertram1, Kristina Döring3, Sascha Dietrich3, Iana Kim4, Stefan Kotschote2, Claus Kuhn4, Konrad Förstner3, Michael Bonin2, Stefan Hannus1, Michael Hannus1

The Good, the Bad and the Ugly: Selective single cell isolation
Sandra Lubos1,2, Nils Körber1, Heide Marie Resch1, Iris Augustin2, Stefan Niehren1

Mixed radiolucent/radio-opaque jaw lesions (schematic radiographic approach)
mohamed osama mostafa , asmaa mohamed abo-gabal